
Last updated: 2026-09-09 19:42:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Septerna, Inc. (SEPN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $38.37, with a market capitalization of $1.72B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.67 to $51.10. This page covers its latest market performance, valuation, price trends and company information.
$1.72B | |
$37.90 | |
$51.10 | |
$4.17 | |
$37.37 | |
321.27K | |
439.99K | |
-- | |
$51.10 | |
$13.67 | |
-- | |
-- |
Septerna, Inc. (SEPN) is currently trading at $38.37 as of 2026-09-09 19:26:29, up 2.68% ($1.00) from the previous close of $37.37
During today's regular trading session, SEPN has traded between $4.17 and $51.10, with a trading volume of 321.27K shares. The current price is near the upper end of today's range.
Over the past seven days, Septerna, Inc. (SEPN) moved from $38.91 to $38.37, representing a decline of 1.39% ($0.54).
The stock traded between $36.01 and $40.95 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 297.08 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66.0%
SEPN is currently trading at $38.37, placing it 66.0% of the way from its 52-week low of $13.67 to its 52-week high of $51.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Septerna, Inc. (SEPN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.